Related Experiment Video

Updated: May 8, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K

Cyclin Dependent Kinase 2 (CDK2) Inhibitors in Oncology Clinical Trials: A Review

Isabelle House1, Mari Valore-Caplan1, Elijah Maris1

  • 1Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.

Journal of Immunotherapy and Precision Oncology
|January 15, 2025
PubMed

Insights

Cyclin dependent kinase 2 (CDK2) inhibitors show promise for treating cancers driven by cell cycle dysregulation. This review covers CDK2 inhibitors in clinical trials, highlighting their potential and observed side effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cyclin dependent kinase 2 (CDK2) regulates the critical G1-S phase transition in the cell cycle.
  • Aberrations in CDK2 signaling are implicated in the pathogenesis of numerous cancers, including breast, ovarian, prostate, leukemia, and lymphoma.
  • Targeting CDK2 represents a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To review the current landscape of CDK2 inhibitors in clinical development.
  • To summarize the efficacy and safety profiles of these agents.
  • To identify patient populations most likely to benefit from CDK2 inhibition.

Main Methods:

  • Literature search of preclinical and clinical studies on CDK2 inhibitors.
  • Analysis of data from ongoing and completed clinical trials.
  • Review of molecular mechanisms and clinical outcomes.

Main Results:

  • CDK2 inhibitors have demonstrated promising preclinical and early clinical activity.
  • The efficacy of CDK2 inhibitors may be most pronounced in cancers with overactive cyclin E.
  • Commonly observed side effects include nausea, vomiting, diarrhea, anemia, and fatigue.

Conclusions:

  • CDK2 inhibitors are a developing class of targeted cancer therapies.
  • Further clinical investigation is warranted to optimize their use in specific cancer types.
  • Understanding the role of cyclin E overactivity can guide patient selection for CDK2 inhibitor therapy.
Keywords:
BLU-222CDK2PF-07104091clinical trialcyclin dependent kinase 2

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K
Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.3K

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...